- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Interventions
- Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,167
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 172
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Cancer, Pediatric Cancer, Pediatric Malignancies, Pediatric Sarcoma of Soft Tissue, Adolescent and Young Adult With Brain Cancer
- Interventions
- ARTCan App
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Brain Tumor, Pediatric
- Interventions
- Brief Internet-based Behavioral Activation Intervention
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm
- Interventions
- SC-CAR4BRAIN
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2043
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diffuse Intrinsic Pontine Glioma, Brainstem Glioma
- Interventions
- Not listed
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2030
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Low-grade Glioma, Advanced Solid Tumor
- Interventions
- Tovorafenib
- Drug
- Lead sponsor
- Day One Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 14
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
- Conditions
- COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
- Interventions
- COVID-19 Vaccine Uptake App, General Health App
- Behavioral · Other
- Lead sponsor
- IDeA States Pediatric Clinical Trials Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,934 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Wilmington, Delaware • Honolulu, Hawaii + 12 more
- Conditions
- Pediatric Solid Tumor
- Interventions
- Genetic testing and GAIN report
- Genetic
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 12
- States / cities
- San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Neoplasm Metastasis
- Interventions
- Pembrolizumab, Favezelimab, Favezelimab/Pembrolizumab, Vibostolimab, Pembrolizumab/Vibostolimab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Iowa City, Iowa • Kansas City, Missouri + 6 more
- Conditions
- Stigma
- Interventions
- Pediatric Stigma Education, Pediatric Stigma Standard Education and Adapted Stigma Intervention
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 2,980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
- Interventions
- Omegaven® (fish oil triglycerides) Injectable Emulsion
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
- Conditions
- ALK-activated Tumors
- Interventions
- Ceritinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more
- Conditions
- Chronic Illness, Hematologic Malignancy, Bone Marrow Transplant Infection, Oncology, Sickle Cell Disease
- Interventions
- Guided Imagery, Virtual Reality
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 8 Years to 25 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Milwaukee, Wisconsin • Wauwatosa, Wisconsin
- Conditions
- Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
- Interventions
- Brentuximab vedotin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Kansas City, Missouri • New York, New York + 1 more
- Conditions
- Poverty, Social Determinants of Health, Mobile Applications, Pediatric ALL, Emergencies
- Interventions
- HelpSteps application
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pediatric Cancer
- Interventions
- Promoting Resilience in Stress Management
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Skin Cancer
- Interventions
- Semi-tailored newsletter
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 5 Years to 6 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Brain Neoplasm, Recurrent Brain Neoplasm
- Interventions
- Cognitive Assessment, Computer-Assisted Cognitive Training, Psychosocial Assessment and Care, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 27
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 24 more
- Conditions
- Pediatric Cancer
- Interventions
- Medically tailored meals
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Malignant Central Nervous System Neoplasm
- Interventions
- Intensity-Modulated Proton Therapy, Magnetic Resonance Imaging
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Solid Tumors, CNS Tumors
- Interventions
- Entrectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Acute Myeloid Leukemia, Pediatric AML
- Interventions
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas